Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PVSRIPO||PVS-RIPO|NSC-719277|NSC719277||PVSRIPO is an oncolytic virus comprising a recombinant poliovirus/rhinovirus chimera, which targets CD155 (Necl5)-expressing tumor cells, and potentially induces enhanced anti-tumor immune response and tumor cell cytotoxicity (PMID: 21984883, PMID: 24939611).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||glioblastoma||not applicable||PVSRIPO||Phase I||Actionable||In a Phase I clinical trial, treatment with PVSRIPO by convection-enhanced delivery in patients with recurrent grade IV malignant glioma demonstrated safety and resulted in a median overall survival (OS) of 12.5 months, compared to 11.3 months in historical controls, and a 24-month and 36-month OS of 21% (95% CI, 11 to 33), compared to 14% and 4%, respectively in historical controls (PMID: 29943666; NCT02986178).||29943666|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02986178||Phase II||Lomustine + PVSRIPO PVSRIPO||PVSRIPO With/Without Lomustine||Active, not recruiting||USA||0|
|NCT03564782||Phase I||PVSRIPO||Examining Bioactivity of PVSRIPO in Invasive Breast Cancer||Recruiting||USA||0|
|NCT04577807||Phase II||PVSRIPO + unspecified PD-1 antibody PVSRIPO||PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma||Recruiting||USA||0|
|NCT03712358||Phase I||PVSRIPO||PVSRIPO for Patients With Unresectable Melanoma||Active, not recruiting||USA||0|